Αποτελέσματα Αναζήτησης
APPROACH TO MANAGEMENT. As with all patients with cancer, ... Yarchoan R, et al. Anti-PD-1 and anti-PD-L1 monoclonal antibodies in people living with HIV and cancer. Curr HIV/AIDS Rep. 2020;17:547–556. doi: 10.1007/s11904-020-00525-y. ... Articles from Journal of Clinical Oncology are provided here courtesy of American Society of Clinical ...
- Immunotherapy in People With HIV and Cancer - PMC - National Center for ...
Studying immunotherapy in people with HIV and cancer will...
- HIV-Associated Cancer Biomarkers: A Requirement for Early Diagnosis
Among HIV-infected individuals, the increased risk for...
- Management of HIV infection in patients with cancer receiving ...
This review focuses on what infectious disease specialists...
- Immunotherapy in People With HIV and Cancer - PMC - National Center for ...
2 Ιουν 2023 · Treating HIV-associated cancers requires a multidisciplinary team to manage concurrent opportunistic infections, potential drug-drug interactions, and the co-occurrence of more than one cancer in the same patient.
28 Αυγ 2019 · Studying immunotherapy in people with HIV and cancer will advance clinical care of all people living with HIV and presents a unique opportunity to gain insight into mechanisms for HIV eradication. Keywords: HIV, immunotherapy, HIV reservoir, cancer, PD-1, Kaposi sarcoma, lymphoma.
29 Ιουλ 2021 · Among HIV-infected individuals, the increased risk for developing cancer is due to the immune system of the patient being suppressed, frequent coinfection with oncogenic viruses and an increase in risky behavior such as poor lifestyle.
1 Ιουλ 2014 · This review focuses on what infectious disease specialists need to know to select the most appropriate ART regimens for patients receiving chemotherapy. Keywords: AIDS; HIV; antiretrovirals; cancer.
11 Μαρ 2014 · The authors provide an update of epidemiological data and diagnostic issues, and discuss the most-appropriate strategies for the management of patients with both HIV and lymphomas.
1 Σεπ 2011 · Highly active antiretroviral therapy (HAART) has substantially reduced morbidity and mortality of AIDS-related complications in patients with HIV; however, the prevalence of AIDS-defining cancers and non-AIDS-defining cancers has increased.
